Duchenne and Becker muscular dystrophies (DMD and BMD, respectively) are caused by mutations in the dystrophin gene, leading to the […]
RENO, N.V., Sept. 15, 2023 /Businesswire/ — Strykagen Corp. the exclusive research partner of Sarcomatrix Therapeutics, Corp., a clinical-stage biotechnology company focused on
RENO, NEVADA Mar. 10, 2023 /PRNewswire/ – Sarcomatrix acquired rhLaminin-111 as a potential treatment for LAMA2-Related Dystrophies, a rare, life-threatening
Your investment can help us accelerate pre-clinical research and move on to in-human trials so we can start offering treatments as soon as possible.
